Maze Therapeutics SEC Filings

Maze Therapeutics insider award: Atul Dandekar, listed as CSBO and officer, was granted 25,000 restricted stock units (RSUs) on 09/22/2025. Each RSU represents a contingent right to one share of Maze Therapeutics common stock upon settlement. The award vests in two equal installments: 12,500 RSUs on September 1, 2026 and 12,500 RSUs on September 1, 2027, subject to the reporting persons continued service on each vesting date. The RSUs do not expire and will either vest or be cancelled prior to the vesting dates. After the grant, the reporting person beneficially owns 25,000 shares (directly) from this award. The Form 4 was signed by an attorney-in-fact on 09/24/2025.

Jason V. Coloma, Chief Executive Officer and Director of Maze Therapeutics (MAZE), was granted 100,000 restricted stock units (RSUs) on 09/22/2025. Each RSU converts to one share of common stock upon settlement and the grant carries a $0 per-share price. The award vests in two equal installments: 50,000 RSUs on September 1, 2026 and 50,000 RSUs on September 1, 2027, contingent on continued service. The RSUs do not have an expiration date and will be cancelled if unvested prior to vesting.

Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc. (MAZE), reported the grant of 40,000 restricted stock units (RSUs) on 09/22/2025. Each RSU represents a contingent right to one share of common stock upon settlement. The award vests in two equal installments: 20,000 RSUs vest on September 1, 2026 and 20,000 RSUs vest on September 1, 2027, subject to continued service. The RSUs have no exercise price and do not expire; they either vest or are cancelled prior to vesting. The reported ownership following the grant is 40,000 shares held directly. The Form 4 was signed by an attorney-in-fact on 09/24/2025.

Amy Bachrodt, SVP Finance of Maze Therapeutics (MAZE), was granted 22,000 restricted stock units on 09/22/2025. Each unit converts to one share of common stock upon settlement and the reporting person beneficially owns 22,000 shares after the reported transaction.

The award vests in two equal installments: 11,000 RSUs on September 1, 2026 and 11,000 RSUs on September 1, 2027, contingent on continued service. The RSUs have no expiration; they either vest or are cancelled before vesting. The Form 4 was executed by an attorney-in-fact on 09/24/2025.

Maze Therapeutics director Daniel K. Spiegelman received a stock option award on 09/22/2025. The Form 4 shows an option to buy 18,000 shares of Maze common stock at an exercise price of $23.67 per share. The option was reported as acquired on 09/22/2025 and is recorded as directly beneficially owned with 18,000 shares following the transaction. The option has an expiration/exercise date shown as 09/21/2035 and vests monthly in nine equal tranches (1/9 each) beginning with a first tranche vesting on October 1, 2025, subject to continued service. The filing was signed by an attorney-in-fact on 09/24/2025.

Catherine A. Sohn, a director of Maze Therapeutics, Inc. (MAZE), was granted a stock option on 09/22/2025 to purchase 18,000 shares of common stock at an exercise price of $23.67 per share. The option award vests monthly as to 1/9 of the total award, with the first tranche vesting on October 1, 2025, subject to continued service. The reported derivative shows 18,000 underlying shares and the reporting person is listed as owning 18,000 shares directly following the transaction. The form was signed by an attorney-in-fact on 09/24/2025.

Maze Therapeutics director Richard H. Scheller was granted a stock option for 18,000 shares on 09/22/2025 at an exercise price of $23.67 per share. The option is exercisable under an agreement that vests in nine equal monthly tranches (1/9 monthly) with the first tranche scheduled to vest on October 1, 2025, subject to continued service. The option has an expiration date shown as 09/21/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/24/2025.

Maze Therapeutics director Jonathan E. Lim received a grant of stock options. The Form 4 reports an award of 18,000 stock options with an exercise price of $23.67, dated 09/22/2025. The options have an exercise price of $23.67 and underlying 18,000 shares of common stock, with an expiration date of 09/21/2035.

The filing states the option vests monthly as to 1/9 of the total award, beginning with a first tranche vesting on 10/01/2025, subject to continued service. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/24/2025.

Kathiresan Sekar, a director of Maze Therapeutics, Inc. (MAZE), reported the acquisition on 09/22/2025 of a stock option to buy 18,000 shares of common stock with an exercise price of $23.67. The option award vests in nine equal monthly tranches (1/9 each) beginning October 1, 2025, subject to continued service. The option shows an expiration or related date of 09/21/2035 and is reported as direct beneficial ownership. The Form 4 was signed by an attorney-in-fact, Courtney Phillips, on 09/24/2025.